PB272 COMBINATION WITH XELODA PB272 COMBINATION WITH TORISEL PB272 SINGLE AGENT/ COMBINATION PB272 COMBINATION WITH CHEMOTHERAPY PB272 COMBINATION WITH PACLITAXEL PB272 SINGLE AGENT PB272 (oral) COMBINATION AND SINGLE AGENT PB272 (oral) SINGLE AGENT PB272 (oral) SINGLE AGENT Metastatic Breast Cancer Metastatic Breast Cancer Metastatic Breast Cancer with Brain Mets Neoadjuvant Breast Cancer Metastatic Breast Cancer Adjuvant Breast Cancer HER2 Mutated NSCLC HER2 Mutated Breast Cancer HER2 Mutated Solid Tumors Phase III Phase II Phase I Pre-Clinical Drug Indication Registration unfolding Puma Biotechnology is focused on the  clinical development of its lead product  candidate PB272,  neratinib (oral) , for the  treatment of breast cancer, non-small cell  lung cancer and other types of solid  tumors with a HER2 mutation. Puma’s clinical trial pipeline is  summarized in the table above. Additional information on Puma’s  clinical trials is available at  www.clinicaltrials.gov.